Google
 
Web www.vitaminlore.com
www.eniva.com

Zafirlukast

Also indexed as: Accolate®

Zafirlukast is used in the prevention and treatment of mild to severe asthma, seasonal allergic asthma, exercise-induced asthma, and aspirin-induced asthma. It belongs to a class of drugs called leukotriene-receptor antagonists (LTRA).

Interactions with Herbs

Willow (Salix alba)
Willow bark contains salicin, a substance similar to aspirin. Research has shown that aspirin significantly increases blood levels of zafirlukast,1 which would increase the likelihood of side effects from zafirlukast. The same thing could theoretically happen if people took willow bark along with zafirlukast, although no studies have investigated this specific interaction. People may want to avoid combining willow bark with zafirlukast due to the possibility of increased side effects.

Interactions with Foods and Other Compounds

Food
The ingestion of food along with zafirlukast can reduce the overall absorption of the drug by about 40%.2 Therefore, zafirlukast should be taken one hour before or two hours after a meal.

Summary of Interactions

Depletion or interference None known
Adverse interaction Willow*
Side effect reduction/prevention None known
Supportive interaction None known
Reduced drug absorption/bioavailability Food

For the convenience of the reader, the information in the summary is categorized as follows: “Depletion or interference” indicates the drug may deplete or interfere with the absorption or function of the supplement or herb. “Adverse interaction” indicates that the supplement or herb used together with the drug may result in undesirable effects. “Side effect reduction/prevention” indicates the supplement or herb may reduce the likelihood and/or severity of a potential side effect caused by the drug. “Supportive interaction” indicates the supplement or herb may support or aid the function of the drug. “Reduced drug absorption/bioavailability” indicates that the supplement or herb may decrease the absorption and/or activity of the drug in the body. An asterisk (*) next to an item in the summary indicates that the interaction is supported only by weak, fragmentary, and/or contradictory scientific evidence.

References:

1. Kelloway JS. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother 1997;31(9):1012–21.

2. Kelloway JS. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother 1997;31(9):1012–21.